Biotage Valuation
Is BIOT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BIOT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BIOT (SEK160.9) is trading below our estimate of fair value (SEK313.79)
Significantly Below Fair Value: BIOT is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BIOT?
Other financial metrics that can be useful for relative valuation.
| What is BIOT's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | SEK 12.87b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 6.3x |
| Enterprise Value/EBITDA | 27.1x |
| PEG Ratio | 2.7x |
Price to Earnings Ratio vs Peers
How does BIOT's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 83x | ||
ALIF B AddLife | 195.8x | 56.3% | SEK 15.3b |
MCAP MedCap | 38.1x | n/a | SEK 7.7b |
GENO Genovis AB (publ.) | 59.1x | 13.6% | SEK 1.8b |
MAGLE Magle Chemoswed Holding | 38.9x | 35.4% | SEK 475.2m |
BIOT Biotage | 54.5x | 20.0% | SEK 12.9b |
Price-To-Earnings vs Peers: BIOT is good value based on its Price-To-Earnings Ratio (54.5x) compared to the peer average (83x).
Price to Earnings Ratio vs Industry
How does BIOT's PE Ratio compare vs other companies in the European Life Sciences Industry?
Price-To-Earnings vs Industry: BIOT is expensive based on its Price-To-Earnings Ratio (54.5x) compared to the European Life Sciences industry average (36.6x).
Price to Earnings Ratio vs Fair Ratio
What is BIOT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 54.5x |
| Fair PE Ratio | 52.8x |
Price-To-Earnings vs Fair Ratio: BIOT is expensive based on its Price-To-Earnings Ratio (54.5x) compared to the estimated Fair Price-To-Earnings Ratio (52.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | SEK 160.90 | SEK 190.00 +18.1% | 11.4% | SEK 210.00 | SEK 160.00 | n/a | 3 |
| Jun ’25 | SEK 185.40 | SEK 173.33 -6.5% | 10.9% | SEK 200.00 | SEK 160.00 | n/a | 3 |
| May ’25 | SEK 168.00 | SEK 186.67 +11.1% | 10.1% | SEK 200.00 | SEK 160.00 | n/a | 3 |
| Apr ’25 | SEK 181.90 | SEK 186.67 +2.6% | 10.1% | SEK 200.00 | SEK 160.00 | n/a | 3 |
| Mar ’25 | SEK 176.50 | SEK 186.67 +5.8% | 10.1% | SEK 200.00 | SEK 160.00 | n/a | 3 |
| Feb ’25 | SEK 143.70 | SEK 165.33 +15.1% | 4.6% | SEK 176.00 | SEK 160.00 | n/a | 3 |
| Jan ’25 | SEK 133.70 | SEK 155.00 +15.9% | 3.2% | SEK 160.00 | SEK 150.00 | n/a | 2 |
| Dec ’24 | SEK 125.00 | SEK 155.00 +24.0% | 3.2% | SEK 160.00 | SEK 150.00 | n/a | 2 |
| Nov ’24 | SEK 114.60 | SEK 155.00 +35.3% | 3.2% | SEK 160.00 | SEK 150.00 | n/a | 2 |
| Apr ’24 | SEK 132.20 | SEK 211.50 +60.0% | 24.3% | SEK 263.00 | SEK 160.00 | SEK 181.90 | 2 |
| Mar ’24 | SEK 149.80 | SEK 254.00 +69.6% | 3.5% | SEK 263.00 | SEK 245.00 | SEK 176.50 | 2 |
| Feb ’24 | SEK 163.10 | SEK 239.00 +46.5% | 10.0% | SEK 263.00 | SEK 215.00 | SEK 143.70 | 2 |
| Jan ’24 | SEK 185.50 | SEK 249.00 +34.2% | 5.6% | SEK 263.00 | SEK 235.00 | SEK 133.70 | 2 |
| Dec ’23 | SEK 189.30 | SEK 249.00 +31.5% | 5.6% | SEK 263.00 | SEK 235.00 | SEK 125.00 | 2 |
| Nov ’23 | SEK 180.30 | SEK 249.00 +38.1% | 5.6% | SEK 263.00 | SEK 235.00 | SEK 114.60 | 2 |
| Oct ’23 | SEK 166.80 | SEK 249.00 +49.3% | 5.6% | SEK 263.00 | SEK 235.00 | SEK 107.40 | 2 |
| Sep ’23 | SEK 172.60 | SEK 249.00 +44.3% | 5.6% | SEK 263.00 | SEK 235.00 | SEK 118.40 | 2 |
| Aug ’23 | SEK 210.40 | SEK 249.00 +18.3% | 5.6% | SEK 263.00 | SEK 235.00 | SEK 127.00 | 2 |
| Jul ’23 | SEK 182.60 | SEK 241.50 +32.3% | 8.9% | SEK 263.00 | SEK 220.00 | SEK 134.20 | 2 |
Analyst Forecast: Target price is less than 20% higher than the current share price.